Abiopharma

🔍 Ring Christine (Executive)

Company: Nurix Therapeutics, Inc. (NRIX)

Report Date: 2026-01-20

Detailed Transactions and Holdings:

• Acquired 3,760 shares of Common Stock at $1.86 per share (Direct)
  Date: 2026-01-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 54,657.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 3,760 shares of Common Stock at $18.4237 per share (Direct)
  Date: 2026-01-20 | Code: S | equity_swap_involved: 0 | shares_owned_after: 50,897.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 3,760 shares of Employee Stock Option (right to buy) at $1.86 per share (Derivative)
  Date: 2026-01-20 | Code: M | Expires: 2029-09-30 | equity_swap_involved: 0 | shares_owned_after: 8,643.00 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: This transaction was effected pursuant to a Rule 10b5-1 trading plan previously adopted by the Reporting Person.
• F2: Represents the weighted average sale price. The lowest price at which shares were sold was $18.18 and the highest price at which shares were sold was $18.69. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.
• F3: The option vested as to 1/4 of the total shares on September 9, 2020, and then 1/48 of the total shares vested monthly thereafter until the option was fully vested on August 9, 2023.